ArticleImmunology2009
Dynamics of the CD8 T-cell response following yellow fever virus 17D immunization.
Article in Immunology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 40 citations in OpenAlex.
- Development of antigen-specific memory CD8+ T cells following live-attenuated chimeric West Nile virus vaccination.The Journal of infectious diseases · 2011Trial
- CD8Cell reports. Medicine · 2026Review
- Regulation of CD45 isoforms during human effector and memory CD8 T cell differentiation: Implications for T cell nomenclature.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Human T Cell Responses to Flavivirus Vaccines.European journal of immunology · 2025Review
- Enhancing Inactivated Yellow Fever 17D Vaccine-Induced Immune Responses in Balb/C Mice Using Alum/CpG.Vaccines · 2023Article
- Large clones of pre-existing T cells drive early immunity against SARS-COV-2 and LCMV infection.iScience · 2023Article
- Longitudinal Characterization of the Mumps-Specific HLA-A2 Restricted T-Cell Response after Mumps Virus Infection.Vaccines · 2021Article
- Zika virus infection during pregnancy protects against secondary infection in the absence of CD8Virology · 2021Article
- How age and infection history shape the antigen-specific CD8Aging cell · 2020Review
- Dynamic changes in circulating T follicular helper cell composition predict neutralising antibody responses after yellow fever vaccination.Clinical & translational immunology · 2020Article
- T-Cell Response to Viral Hemorrhagic Fevers.Vaccines · 2019Review
- Stable Frequencies of HLA-CFrontiers in immunology · 2018Article
- A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.Journal of immunology (Baltimore, Md. : 1950) · 2017Article
- Adaptive immune responses to booster vaccination against yellow fever virus are much reduced compared to those after primary vaccination.Scientific reports · 2017Article
- The 17D-204 Vaccine Strain-Induced Protection against Virulent Yellow Fever Virus Is Mediated by Humoral Immunity and CD4+ but not CD8+ T Cells.PLoS pathogens · 2016Article
- Characterization of Yellow Fever Virus Infection of Human and Non-human Primate Antigen Presenting Cells and Their Interaction with CD4+ T Cells.PLoS neglected tropical diseases · 2016Article
- Article
- Guiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccine.Cellular & molecular immunology · 2016Review
- Dynamics of the cytotoxic T cell response to a model of acute viral infection.Journal of virology · 2015Article
- The yellow fever 17D virus as a platform for new live attenuated vaccines.Human vaccines & immunotherapeutics · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Management of yellow fever is focused on the prevention of illness by the use of the yellow fever virus (YFV) 17D vaccine. The role of neutralizing antibodies in protection is generally accepted with YFV-specific T cells likely contributing to the control of viral replication. We studied CD8(+) T-cell responses to four defined human leucocyte antigen-B35-restricted epitopes in YFV vaccine recipients as a model of the kinetics of cytotoxic T-lymphocyte responses to an acute human viral infection. Multiple features of these epitope-specific responses were analysed after vaccination including magnitude, cytokine production, phenotype and T-cell receptor repertoire. Peak peptide-specific interferon-gamma (IFN-gamma) responses of almost 1% of CD8(+) T cells were seen as early as 2 weeks post-vaccination; however, dominant responses varied between donors. Peptide-specific responses were still detectable at 54 months post-vaccination. Tetramer-positive cells, at high frequencies, were detected as early as 7-9 days, before detectable IFN-gamma-producing cells, suggesting a defect in the functional capacity of some antigen-specific cells early post-vaccination. The predominant memory phenotype of the tetramer-positive population was a differentiated effector (CD45RA(+) CCR7(-) CD62L(-)) phenotype. The T-cell receptor Vbeta analysis revealed a diverse oligoclonal repertoire in tetramer-positive T-cell populations in two individuals. These characteristics of the YFV-specific T-cell response could contribute to vaccine effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.